We asked 103 gastroenterologists in the U.S. for their opinion on the diagnosis and treatment of C. difficile infections (CDI).

To understand physician's evolving practice patterns and knowledge of C.difficile infections, KeyOps teamed up with Dr. Jessica Allegretti to survey 103 US gastroenterologists about CDI testing and treatment.

Dr. Jessica Allegretti is the director of the fecal microbiota transplant program at Brigham and Women’s Hospital, and is leading several clinical trials investigating the use of fecal transplantation in chronic diseases such as IBD and Primary Sclerosing Cholangitis
‍‍
Executive Summary:
‍
  • Who: 103 US-based gastroenterologists
  • What: Diagnosis and treatment of C. difficile infections
  • How: Recruited over 100+ GIs within 1 week to a qualitative nationwide survey
  • What we discovered:‍
  • 81% of GIs see up to 5 CDI patients a month.
  • 71% of physicians identified that GDH reflexed to EIA testing is the recommended testing modality to diagnose CDI
  • 57% of physicians currently offer FMT as a treatment option
  • 83% of GIs plan to use microbiome-based therapeutics once approved in lieu of FMT.

Below is a detailed summary of responses to individual questions as well as anonymous comments from the KeyOps community.

Thank you for your valuable insights!
doctors animation

The client can proceed with a medical education strategy that targets a broad array of medical oncologists. Communication will focus on specific stages of the patient journey and the data that support the new test’s use in these stages. The pricing insight also helps forecast the size of the market opportunity.

64% of physicians order 2 or more tests for CDI per month

The majority send more than 2 tests per month

GDH reflexed to EIA toxin testing is the most commonly available test followed by PCR

Openbiome is the most frequently used source for donor material

Most commonly cited reasons for not offering FMT is COVID related issues and lack of resources (for e.g. experience, personnel, facility)

What benefits do you believe micro-biome based therapeutics have above FMT?Physicians believe microbiome-based therapeutics are more effective and easier to use

17% of physicians do not intend to offer FMT

Most commonly cited reasons are the need to learn more and limited efficacy

Respondent profile

57%

Male respondents

43%

Female respondents

trophy icon

Top 3 most insightful comments as selected by Dr Allegretti:

"Decreased risk of infection, improved patient acceptance of treatment modality "
(GI, Massachusetts)
"Non-invasive administration"
(GI, Dr. Ari Grinspan, New York)
"FMT not widely available and other therapies will provide more accessible option if clinically effective" (GI, Dr. Joy Liu, Illinois)
keyops logo white
We’re changing the world of physician engagement
©2022 KeyOps.io 155 Queens Quay E, Suite 200 Box 87, Toronto, ON. M5A 0W4| contact@keyops.io